Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype

P T. 2017 Sep;42(9):564-568.

Abstract

Reslizumab (Cinqair), an interleukin-5 antagonist for severe eosinophilic asthma.